The clinical significance of palivi-zumab in the prevention of severe respiratory infections in newborn infants
Year: 2016, volume 12 Issue: №2 Pages: 165-167
Heading: Pediatrics Article type: Case report
Authors: Bykova Е.М., Gavrilova E.S., Borisova А.А., Pazgalyova N.V., Panina O.S., Chernenkov Yu.V.
Organization: Saratov State Medical University
Heading: Pediatrics Article type: Case report
Authors: Bykova Е.М., Gavrilova E.S., Borisova А.А., Pazgalyova N.V., Panina O.S., Chernenkov Yu.V.
Organization: Saratov State Medical University
Summary:
Palivizumab is known as the world's first drug with proven efficacy for passive immunization of severe infections of lower respiratory tract in preterm infants. The paper describes a clinical case of application of palivizumab (sinagis) at a newborn infant with bronchopulmonary dysplasia complicated by episodes of obstructive bronchitis. Particular attention is paid to the mechanism of action of palivizumab on the respiratory syncytial virus providing the data on a clinical picture of respiratory syncytial virus infection in a premature baby and showing the effectiveness of the drug in infants.
Bibliography:
1. Vozianova Zh.l. Infectious and parasitic diseases. Kiev: Zdorov'e, 2002; 904 p.
2. Baraldi Е, Zanconato S, Carraro С. Bronchiolitis: from empiricism to scientific evidence. Lechaschiy vrasch 2011
3. Federal state statistics service, http://www.gks.ru
4. Ovsyannikov D.Yu., Degtyarev D.N., Korsunsky A.A., et al. Respiratory syncytial virus bronchiolitis in preterm children in clinical practice. Pediatrics 2014; 3 (93): 34-36
5. Silva С, Dias L, Baltieri S, et al. Respiratory syncytial virus outbreak in neonatal intensive care unit: Impact of infection control measures plus palivizumab use. Antimicrob Resist Infect Control 2012; 10: 1-16
6. Ovsyannikov D.Yu., Degtyareva E.A., Kuzmenko L.G. The risk Group of severe respiratory-syncytial viral infection in children: modern possibilities of prevention. Pediatric infections 2011; 2: 49-51
7. The outcome of the expert meeting on prevention of acute respiratory infections in children under the age of 2 years. Pediatric pharmacology 2012; 2 (9): 159-160
8. Kulichenko T.V. Palivizumab: new opportunities for prevention of severe forms of PC virus infection in children. Pediatric pharmacology 2010; 4 (7): 40-43
9. Checchia P.A., Nalysnyk L., Fernandes A.W., et al. Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receving prophilaxis with palivizumab: A systematic literature review and metanalysis. Pediatr Crit Care Med2011; 12 (5): 580-589.
| Attachment | Size |
|---|---|
| 2016_02_165-167.pdf | 221.05 KB |
Русский
English